Emerging role of non-coding RNAs in the regulation of KRAS

被引：0
作者：
Soudeh Ghafouri-Fard
Zeinab Shirvani-Farsani
Bashdar Mahmud Hussen
Mohammad Taheri
Reza Jalili Khoshnoud
机构：
[1] Shahid Beheshti University of Medical Sciences,Department of Medical Genetics, School of Medicine
[2] Shahid Beheshti University,Department of Cellular and Molecular Biology, Faculty of Life Sciences and Technology
[3] Hawler Medical University,Department of Pharmacognosy, College of Pharmacy
[4] Jena University Hospital,Institute of Human Genetics
[5] Shahid Beheshti University of Medical Sciences,Urology and Nephrology Research Center
[6] Shahid Beheshti University of Medical Sciences,Skull Base Research Center, Loghman Hakim Hospital
来源：
Cancer Cell International | / 22卷
关键词：
KRAS; Oncogene; lncRNA; miRNA; circRNA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The Kirsten ras oncogene KRAS is a member of the small GTPase superfamily participating in the RAS/MAPK pathway. A single amino acid substitution in KRAS gene has been shown to activate the encoded protein resulting in cell transformation. This oncogene is involved in the malignant transformation in several tissues. Notably, numerous non-coding RNAs have been found to interact with KRAS protein. Such interaction results in a wide array of human disorders, particularly cancers. Orilnc1, KIMAT1, SLCO4A1-AS1, LINC01420, KRAS1P, YWHAE, PART1, MALAT1, PCAT-1, lncRNA-NUTF2P3-001 and TP53TG1 are long non-coding RNAs (lncRNAs) whose interactions with KRAS have been verified in the context of cancer. miR-143, miR-96, miR-134 and miR-126 have also been shown to interact with KRAS in different tissues. Finally, circITGA7, circ_GLG1, circFNTA and circ-MEMO1 are examples of circular RNAs (circRNAs) that interact with KRAS. In this review, we describe the interaction between KRAS and lncRNAs, miRNAs and circRNAs, particularly in the context of cancer.
引用
收藏
相关论文
共 420 条
[1]  
Chang EH(1982)Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses Proc Natl Acad Sci 79 4848-4852
[2]  
Gonda MA(1983)Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene Nature 304 501-506
[3]  
Ellis RW(1997)A new function of p120-GTPase-activating protein J Biol Chem 272 25128-25134
[4]  
Scolnick EM(1983)Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas Cell 32 201-208
[5]  
Lowy DR(2010)Clinical relevance of KRAS in human cancers J Biomed Biotechnol 120 3397-3406
[6]  
McGrath JP(2012)Targeting oncogenic Ras signaling in hematologic malignancies Blood J Am Soc Hematol 33 78-87
[7]  
Capon DJ(2014)KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia Cell Physiol Biochem 8 66087-2467
[8]  
Smith DH(2017)KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia Oncotarget 9 1199-3757
[9]  
Chen EY(2019)RAS as supporting actor in breast cancer Front Oncol 13 1204-2896
[10]  
Seeburg PH(2021)Targeting KRAS in cancer: promising therapeutic strategies Cancers 72 2457-1052
12345678910